(Corrects headline and paragraph 1 to drop reference to Ultomiris being an ALS drug)
(Reuters) – British drugmaker AstraZeneca Plc will pay $775 million to settle a patent dispute with Japan’s Chugai Pharmaceutical Co Ltd related to rare disease treatment Ultomiris, it said on Thursday.
The settlement would not affect AstraZeneca’s financial forecasts for 2022, it said.
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Rashmi Aich)
